Abstracts Archive - Page 111 of 2607 - ACR Meeting Abstracts

Abstract Number: 1247 • ACR Convergence 2025
Relation of Measures of Pain Sensitization to Widespread Pain
ZHIQIANG WANG¹, Sarah Tilley², Laura Frey Law³, Cora Lewis⁴, Michael Nevitt⁵, Kosaku Aoyagi⁶, Chunyi Wen⁷, Changhai Ding¹ and Tuhina Neogi⁸, ¹Zhujiang Hospital, Southern Medical University, Guangzhou, China (People's Republic), ²Boston University School of Medicine, Somerville, MA, ³Department of Physical Therapy and Rehabilitation Science, Carver College of Medicine, University of Iowa, Iowa City, IA, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵University of California, San Francisco, San Francisco, CA, ⁶University of Texas at El Paso, El Paso, TX, ⁷The Hong Kong Polytechnic University, Hong Kong, China (People's Republic), ⁸Boston University School of Medicine, Boston, MA
Background/Purpose: Widespread pain (WSP) is thought to be related to alterations in nociceptive signaling such as pain sensitization. Whether pain sensitization predisposes to an increase…
Abstract Number: 1244 • ACR Convergence 2025
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Rosemary Hollick¹, Marcus Beasley¹, Ernest Choy², Caroline Cupit³, Debra Dulake¹, Teresa Finlay³, Louise Locock¹, Paul McNamee¹, Catherine Pope³, Elaine Wainwright¹, David Williams⁴ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University of Michigan, Michigan
Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…
Abstract Number: 1305 • ACR Convergence 2025
Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study
Nina Shirman¹, Liora Harel², Gil Amarilyo³, Kfir Kaidar⁴, Yonatan Butbul Aviel⁵, Merav Heshin Bekenstein⁶, Mohamad Hamad Saied⁷, Ofra Goldzweig⁸, Adi Miler⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israe, Tel Aviv, Israel, ²Schneider Children's Medical center, Nettnja, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴Pediatric rheumatology, Schneider children's medical center of Israel, Petah Tikva, Israel, ⁵Pediatric rheumatology, Technion Faculty of Medicine, Haifa, Israel, ⁶Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ⁷Carmel Medical Centre, Technion Faculty of Medicine, Haifa, Israel, ⁸Pediatric rheumatology unit, Kaplan medical canter, Rehovot, Israel, ⁹Pediatric rheumatology unit, Technion Faculty of Medicine, Haifa, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is an autoinflammatory disease following SARS-CoV-2 exposure. The optimal treatment strategy remains under investigation, though intravenous immunoglobulin (IVIG)…
Abstract Number: 1024 • ACR Convergence 2025
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Marta Ruiz-Valdepeñas Almansa¹, CLARA DE MIGUEL², DALIFER FREITES³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Olga Sanchez Pernaute⁵, fredeswinda Romero-Bueno⁶, Mª Jesus Rodriguez-Nieto⁷, Rosalia Laporta⁸, Hilda Godoy Tundidor⁹, Jesús Loarce¹⁰, Juan A Rigual¹¹ and lydia Abasolo Alcazar¹², ¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Clinica Universidad de Navarra, Madrid, Madrid, Spain, ⁶University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ⁷Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁸Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Hospital Universitario puerta de hierro, Madrid, Spain, ¹⁰HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…
Abstract Number: 1343 • ACR Convergence 2025
Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
Sung Hae Chang¹, You-Jung Ha², Sung Won Lee³, Misti Paudel⁴, Gregory McDermott⁵, Qianru Zhang⁶, Min Uk Kim⁷, Jeong Seok Lee⁸, Chan Ho Park⁹, Ji-Won Kim¹⁰, Jang Woo Ha¹¹, SANGWAN CHUNG¹², Eun Ha Kang¹³, Yeon-Ah Lee¹², Yong-Beom Park¹⁴, Jung-Yoon Choe¹⁵, Eun Young Lee¹⁶ and Jeffrey Sparks¹⁷, ¹Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ²Seoul National University Bundang Hospital, Seongnam, South Korea, ³Soon Chun Hyang University Hospital, Seoul, South Korea, ⁴Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Harvard Medical School, Boston, MA, ⁷SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁸Korea Advanced Institute of Science and Technology, KAIST, DaeJeon, Republic of Korea, ⁹Soonchunhyang University College of Medicine, Cheonan, Republic of Korea, ¹⁰Daegu Catholic University School of Medicine, Nam-gu, Daegu, Republic of Korea, ¹¹Division of Rheumatology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Republic of Korea, ¹²Kyung Hee University Medical Center, seoul, Republic of Korea, ¹³Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ¹⁴Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ¹⁵Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Republic of Korea, ¹⁶Seoul National University College of Medicine, Seoul, South Korea, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The six-minute walk distance (6MWD) measures functional capacity in cardiopulmonary diseases, predicts mortality in interstitial lung disease (ILD), and is used as an endpoint…
Abstract Number: 1313 • ACR Convergence 2025
Retrospective Analysis of Factors Associated With Fracture in 2855 Patients With Rheumatoid Arthritis, Stratified by Steroid Use
Jonathan Barnes¹, Hamzah Amin² and marwan Bukhari³, ¹Morecambe Bay NHS Trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom
Background/Purpose: Steroids are used in a proportion of patients with rheumatoid arthritis (RA). Steroids are known to cause a decrease in bone mineral density (BMD),…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 1184 • ACR Convergence 2025
Does Blocking IL-17 Treat Recalcitrant Uveitis? Explorative Study on the Use of Ixekizumab to Manage Patients with Uveitis.
Sergio Schwartzman¹, Stephen Anesi², Yasmin Massoudi², Monica Schwartzman³ and Peter Chang², ¹Weill Cornell Medical Center, New York Presbyterian Hospital, and Hospital for Special Surgery, New York, NY, ²MERSI, Waltham, ³Hospital for Special Surgery/New York Presbyterian Hospital-Weill Cornell Medical Center, New Rochelle, NY
Background/Purpose: Non-infectious uveitis can exist as a primary autoimmune disease or can be a manifestation of an underlying systemic illness. Despite the availability of new…
Abstract Number: 1204 • ACR Convergence 2025
Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.
Takeshi Yoshida¹, Didem Saygin² and Jemima Albayda³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Rush University Medical Center, Chicago, IL, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The Heckmatt grading scale has been widely used as a semiquantitative assessment method for grading muscle echo intensity (EI) on ultrasound; however, this was…
Abstract Number: 1044 • ACR Convergence 2025
Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Gunjan Rana¹, Mansi Mehta¹ and Joanne Cunha², ¹Saint Vincent Hospital, Worcester, MA, ²BROWN MEDICINE, BROWN UNIVERSITY, Riverside, RI
Background/Purpose: Hydroxychloroquine is a cornerstone in the treatment of Systemic Lupus Erythematosus (SLE), while corticosteroids and immunosuppressive agents are employed for moderate to severe disease…
Abstract Number: 1344 • ACR Convergence 2025
Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
yao fan fang¹, Ping-Han Tsai² and yen Fu CHEN³, ¹Chang Gung memorial hopspital, Linkou, Taipei, New Taipei, Taiwan (Republic of China), ²Chang Gung memorial hospital, linkou, Taipei, Taiwan (Republic of China), ³Chang Gung memoriial hospital linkou, taipei, Taiwan (Republic of China)
Background/Purpose: Tofacitinib is the first oral targeted synthetic disease-modify anti-rheumatic drug for patients with moderate to severe rheumatoid arthritis 1. This study aimed to identify…
Abstract Number: 1288 • ACR Convergence 2025
Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Ivan Foeldvari¹, Kathryn Torok², Ozgur Kasapcopur³, Amra Adrovic⁴, Brian Feldman⁵, Flavio Sztajnbok⁶, Maria Teresa Terreri⁷, Ana Sakamoto⁸, Jordi Anton⁹, Sindhu Johnson¹⁰, Raju Khubchandani¹¹, Valda Stanevica¹², Gülcan Özomay Baykal¹³, Dieneke Schonenberg-Meinema¹⁴, Eslam Al-Abadi¹⁵, Ekaterina Alexeeva¹⁶, Maria Katsicas¹⁷, Sujata Sawhney¹⁸, Vanessa Smith¹⁹, Sima Abu Alsaoud²⁰, Simone Appenzeller²¹, Tadej Avcin²², Natalia Cabrera²³, Stefanie Hajek²⁴, Siri Opsahl Hetlevik²⁵, Mikhail Kostik²⁶, Thomas Lehman²⁷, Suzanne Li²⁸, Hana Malcova²⁹, Edoardo Marrani³⁰, Clare Pain³¹, Anjali Patwardhan³², Walter Alberto Sifuentes-Giraldo³³, Natalia Vasquez-Canizares³⁴, Patricia Costa Reis³⁵, Mahesh Janarthanan³⁶, Maria Jose Santos³⁷, Cristina Battagliotti³⁸, Lillemor Berntson³⁹, blanca e r bica⁴⁰, Jürgen Brunner⁴¹, Liora Harel⁴², Gerd Horneff⁴³, Daniela Kaiser⁴⁴, Jorge Lopez-Benitez⁴⁵, Farzana Nuruzzaman⁴⁶, Mihaela Sparchez⁴⁷, Yosef Uziel⁴⁸ and Nicola Helmus⁴⁹, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²University of Pittsburgh, Pittsburgh, PA, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Turkey, Turkey, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶UFRJ/UERJ, SAO PAULO, Brazil, ⁷UNIFESP, São Paulo, São Paulo, Brazil, ⁸Federal University of São Paulo (UNIFESP), São Paulo, São Paulo, Brazil, ⁹Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ¹⁰Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ¹¹Jaslok Hospital and Research Center, Mumbai, India, ¹²Childrens Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹³Umraniye Training and Research Hospital, Istanbul, Turkey, ¹⁴Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Birmingham Women’s and Children’s Hospital NHSFT, Birmingham, United Kingdom, ¹⁶National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ¹⁷Hospital Garrahan, Buenos Aires, Argentina, ¹⁸Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰Caritas baby Hospital, Jerusalem, Palestine, ²¹Unicamp, Campinas, São Paulo, Brazil, ²²University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²³IPS Central: Asunción, Asuncion, Paraguay, ²⁴Deutsches Zentrum für Kinder- und Jugendrheumatologie, Garmisch-Partenkirchen, Germany, ²⁵Oslo University Hospital, Oslo, Norway, ²⁶Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²⁷Hospital for Special Surgery, New York, ²⁸Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ²⁹Motol University Hospital, Prague, Czech Republic, ³⁰Meyer Children Hospital IRCCS, Firenze, Italy, ³¹Alder Hey NHS Trust, Liverpool, United Kingdom, ³²University of Missouri-Columbia, Columbia, MO, ³³Hospital Universitario Ramón y Cajal, Madrid, Spain, ³⁴Children’s Hospital at Montefiore, Bronx, NY, ³⁵Hospital de Santa Maria, Lisbon, Portugal, ³⁶SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, Tamil Nadu, India, ³⁷Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³⁸Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³⁹Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ⁴⁰UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ⁴¹Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ⁴²Schneider Children's Medical center, Nettnja, Israel, ⁴³Asklepios Klinik, Hamburg, Germany, ⁴⁴Childrens Hospital Lucerne, Lucerne, Switzerland, ⁴⁵Private Practice, Asuncion, Paraguay, ⁴⁶Stony Brook Children's Hospital, Stony Brook, NY, ⁴⁷Emergency Clinical Hospital for Children, Cluj-Napoca, Romania, ⁴⁸Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, ⁴⁹Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Gastroesophageal involvement, particularly reflux, has been identified as a risk factor for development and progression of interstitial lung disease (ILD) in adult systemic sclerosis…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Kristina Ciaglia¹ and Magan Fosso², ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].